Key Details
Price
$337.63Annual ROE
-6.94%Beta
0.75Events Calendar
Next earnings date:
Feb 14, 2025Recent quarterly earnings:
Oct 30, 2024Recent annual earnings:
Feb 15, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Mar 08, 2002Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
MINNEAPOLIS , Nov. 27, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Citi 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 3:15 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
BIO-key (BKYI) Reports Q3'24 Revenue Rose 18% to $2.1M, Reduced Q3'24 Net Loss, Improved Cash Position; Hosts Conf. Call Tomorrow, Fri. Nov. 15th, 10am ET.
R&D Systems Hematology Controls and Calibrators has completed the Class B Certification under the new European Union In Vitro Diagnostic Regulation This press release updates the IVDR Classification to Class B from the prior Class C. MINNEAPOLIS , Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators.
R&D Systems Hematology Controls and Calibrators has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation MINNEAPOLIS , Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. This certification confirms that the products comply with the regulations and guidelines set forth by the European Union for in-vitro diagnostic devices.
MINNEAPOLIS , Nov. 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: UBS Global Healthcare Conference November 12, 2024 9:30 AM PST Stifel 2024 Healthcare Conference November 19, 2024 8:00 AM EST Stephens NASH 2024 Conference November 20, 2024 11:00 AM CST A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.
Examine the evolution of Bio-Rad's (BIO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will participate in the upcoming BIO-Europe 2024 conference in Stockholm. The event will allow Tiziana to engage with industry leaders, potential collaborators, and investors, emphasizing its recent clinical advancements, particularly data from its combination study involving Ozempic, a GLP-1 agonist.
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference's partnering meetings, Tiziana will engage with industry leaders, potential collaborators, and investors to discuss recent clinical progress, including data from its combination study involving Ozempic, a GLP-1 agonist.
Bio-Rad witnesses growth across the Clinical Diagnostics segment in the third quarter, primarily driven by an increased demand for quality control and immunology products.
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Norman Schwartz - Chairman of the Board, President & Chief Executive Officer Jon DiVincenzo - President & Chief Operating Officer Roop Lakkaraju - Executive Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Leonard - UBS Brandon Couillard - Wells Fargo Jack Meehan - Nephron Research Tycho Peterson - Jefferies Operator Hello, everyone, and welcome to today's Bio-Rad Third Quarter 2024 Results Conference Call and Webcast. At this time to get started, all participants are in a listen-only mode.
FAQ
- What is the primary business of Bio-Rad Laboratories?
- What is the ticker symbol for Bio-Rad Laboratories?
- Does Bio-Rad Laboratories pay dividends?
- What sector is Bio-Rad Laboratories in?
- What industry is Bio-Rad Laboratories in?
- What country is Bio-Rad Laboratories based in?
- When did Bio-Rad Laboratories go public?
- Is Bio-Rad Laboratories in the S&P 500?
- Is Bio-Rad Laboratories in the NASDAQ 100?
- Is Bio-Rad Laboratories in the Dow Jones?
- When was Bio-Rad Laboratories's last earnings report?
- When does Bio-Rad Laboratories report earnings?
- Should I buy Bio-Rad Laboratories stock now?